Archives — Current Month (8)
Assure Holdings, an intraoperative neuromonitoring company founded by former NFL quarterback Preston Parsons, will begin trading on the TSX Venture Exchange on May 29, under the trading symbol IOM.
With the market in flux, Chen Lin of the popular newsletter What Is Chen Buying?, What Is Chen Selling? is hedging his bets with investments in a variety of companies in different sectors.
Viveve Medical's Q1/17 results beat expectations, an accomplishment that was welcomed by several industry analysts.
NASH is an epidemic in the U.S., with more than 100 million people believed to be affected. Yet no FDA-approved treatments are available, with the exception of liver transplantation for end-stage disease. In part two of his interview with The Life Sciences Report, Ed Arce, managing director in equity research and senior analyst covering companies in the biopharmaceuticals and specialty pharmaceuticals sectors for H.C. Wainwright, and organizer of the recent inaugural NASH Investor Conference, says that small companies are rushing to fill the pipeline, with numerous compounds in trials.
In light of a decision to pull its application for approval of vosaroxin in the European Union, Sunesis Pharmaceuticals has designated its BTK inhibitor program targeting chronic lymphocytic leukemia as its new lead program.
Big Pharma Sets Its Sights on NASH Epidemic (05/17/2017)
Up to one-third of Americans may have conditions that lead to NASH, yet the disease is far from a household name. Closely linked with obesity, the disease does not become symptomatic until very late stage. Ed Arce, managing director in equity research and a senior analyst covering companies in the biopharmaceuticals and specialty pharmaceuticals sectors for H.C. Wainwright, organized the recent inaugural NASH Investor Conference. In part one of his interview with The Life Sciences Report, Arce discusses the disease, its market potential and how companies large and small are trying to fix the current dearth of treatments.
DURECT and Sandoz Ink $293 Million Deal for POSIMIR (05/10/2017)
DURECT Corp. and Sandoz AG, a division of Novartis, have signed a development and commercialization agreement for the U.S. for POSIMIR.
Mesoblast Ltd., an Australia-based regenerative medicine company currently in a Phase 3 clinical trial in chronic heart failure, has received successful interim data, which prompted the Maxim Group to comment favorably on the study's design and progress.
|"RGS' strategy is to partner its product opportunities for development and commercialisation, allowing it to focus on early-stage product development."|
|"Based on RXI's new checkpoint inhibitors and the potential for multiple partnering deals, we are maintaining our Buy recommendation."|
|"INO continues to advance multiple immunotherapy studies forward, which should provide incremental catalysts for the stock as data emerges."|
|"We initiate with an Outperform on VIVE."|
|"RVX remains gravely undervalued at the current share price."|